Theorist position for analysis 8ec36980-febb-4093-a5a1-387ea5768480: Proteogenomic Network Hubs as Druggable Targets in Early PD Neurodegeneration
Source basis: Key genes and convergent pathogenic mechanisms in Parkinson disease (Nature Reviews Neuroscience, 2024, DOI 10.1038/s41583-024-00812-2). The stored gap context says: Review identified convergent pathogenic mechanisms but highlighted that druggability assessment of network hubs in early PD remains an open challenge.
Primary hypothesis: early PD proteogenomic hubs that are both causal enough and accessible enough to perturb is not merely an associated signature; it is a testable mechanism that can explain the open question: Which proteogenomic network hubs identified by multi-omics PD studies are druggable at the earliest stages of neurodegeneration, what are their protein interaction partners in dopaminergic neurons, and do they show altered accessibility in iPSC-derived PD neuron models carrying SNCA mutations?
Three candidate claims should be carried forward. First, the strongest causal signal should appear in the cell type or tissue compartment named by the question, not only in bulk disease contrasts. Second, perturbing the axis should shift a proximal molecular phenotype before it shifts a late pathology phenotype, which would help separate cause from consequence. Third, the relevant readout should be stratified by SNCA, because collapsing across those terms would erase the mechanism the analysis is trying to test.
The priority experiment is multi-omics network centrality, druggability scoring, interactome validation, and SNCA iPSC-neuron perturbation assays. A positive result would require concordance across human observational data, disease-relevant cellular models, and at least one perturbation that moves the predicted proximal readout in the expected direction.